Plain-English answer
Translate the institution, not just the word. Some U.S. healthcare terms should remain in English with Chinese explanation because a smooth Chinese phrase can erase how the institution works. Medicare, Medicaid, CPT, HCPCS, coverage, reimbursement, prior authorization, value analysis committee, local coverage determination, and FDA clearance each carry institutional meaning that can be lost if translated too broadly. Precision matters commercially and clinically.
Translation principles
The first rule is to keep the decision gate visible. A Chinese reader should know whether a term is about regulation, coding, payer coverage, payment amount, provider purchasing, patient eligibility, privacy, liability, or clinical evidence. The second rule is to avoid false equivalence. "Insurance" in China often refers to a public basic medical insurance structure administered through local pooling and NHSA-related policy. "Insurance" in the United States may mean Medicare, Medicaid, employer coverage, ACA Marketplace coverage, commercial managed care, or self-funded employer plans. The third rule is to explain the consequence, not only the definition. Translation should preserve institutional friction.
Terms to preserve
| Term | Why preserve it | Chinese explanation should include |
|---|---|---|
| Coverage | It is not the same as payment. | Whether a payer accepts medical necessity under defined conditions. |
| Reimbursement | It can mean payment to provider, not patient reimbursement. | Who bills, who pays, how much, and in what care setting. |
| CPT / HCPCS | Coding does not guarantee coverage or payment. | Code ownership, use case, and payer relationship. |
| Medicare / Medicaid | They are different public programs. | Eligibility, federal/state roles, and population covered. |
| FDA clearance / approval | Regulatory permission is not market success. | Product pathway, intended use, evidence, postmarket duties, payment gap. |
| Value analysis committee | Hospital purchasing gate, not a clinical society. | Evidence, economics, supply-chain, workflow, and implementation review. |
Examples
A page for a Chinese medtech company should not translate reimbursement as if the patient simply submits an invoice. The page should explain billing, payer type, code, coverage policy, payment method, and site of care. A page on FDA clearance should not imply the hospital will buy the device. It should explain why FDA, CMS, commercial payers, hospital purchasing, service support, liability, and trust are separate gates. A page on Medicare should not translate it as general "medical insurance"; it is a federal program mainly for older adults and certain disabled or end-stage renal disease populations, with parts and payment systems that matter commercially.
The same rule applies in the other direction. Chinese terms such as basic medical insurance, NRDL, volume-based procurement, tertiary Grade A hospital, internet hospital, and medical alliance should not be flattened into familiar U.S. words. Each term points to a Chinese institution, payer rule, hospital classification, or reform instrument. Good bilingual writing keeps the original institutional structure visible and then explains what decision it affects.
Research anchors
- CMS guide for medical technology companies for the coding, coverage, and payment distinction.
- FDA Device Advice for clearance, approval, and device pathway language.
- Medicaid.gov for Medicaid and CHIP program context.
- MedPAC data books for Medicare program context.